ArticleMikrochimica acta2026
Dual-mode fluorescence and UV-vis aptasensor for hepatocellular carcinoma detection using magnetic separation.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A dual-mode aptasensor based on magnetic separation with a sequential signal conversion mechanism is developed for sensitive and specific detection of HepG2 cells. The system uses magnetic bead-labeled aptamers (MB-Apt, T1 strand), thiol-modified T2-functionalized silver nanoparticles (T2-AgNPs), and CdTe quantum dots (QDs). Without target cells, T2-AgNPs hybridize with MB-T1, leaving no AgNPs in the supernatant (no UV-vis absorption signal) while CdTe QDs produce strong fluorescence. Upon addition of HepG2 cells, aptamers bind to the cells, releasing AgNPs into the supernatant (UV-vis absorption signal). Subsequent acidolysis releases Ag⁺ ions, quenching QD fluorescence via cation exchange (FL signal). The dual signals offer self-validation and high anti-interference. Under optimal conditions, the fluorescence signal is linear from 0 to 2 × 10⁷ cells/mL (R²=0.985) and UV-vis absorption signal shows good linearity (R²=0.978). The sensor exhibits high specificity for HepG2 over other tumor cells. It successfully detects HepG2 cells spiked in human serum with satisfactory recoveries ranging from 96.2% to 102.5% for the fluorescence mode and 94.8% to 98.7% for the UV/colorimetric mode (RSDs < 5.3%), demonstrating its potential for practical clinical application.
Indexed as
Identifiers
42484727What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.